Sustained Response at 2 Years Reported for Deucravacitinib ...Middle East

Medscape - News
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, was approved September 9 by the FDA for treating adults with moderate to severe plaque psoriasis. MDedge News

Hence then, the article about sustained response at 2 years reported for deucravacitinib was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sustained Response at 2 Years Reported for Deucravacitinib )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News